🇺🇸 FDA
Patent

US 10940160

Biomarkers for predicting responsiveness to decitabine therapy

granted A61KA61K31/7068

Quick answer

US patent 10940160 (Biomarkers for predicting responsiveness to decitabine therapy) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/7068